On October 30th, Eli Lilly China announced that its non covalent (reversible) BTK inhibitor, Jepanib (100mg and 50mg tablets of Pitobutinib), has been approved by the National Medical Products Administration (NMPA) for monotherapy in adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two systemic treatments (including Bruton's tyrosine kinase [BTK] inhibitors).